China Regenerative Medicine International Limited
(Stock Code: 8158.HK)

Approval of the Re-registration of “ActivSkin”
The Tissue Engineered Skin Product of CRMI

(3 April, 2018 - Hong Kong) – China Regenerative Medicine International Limited ("CRMI" or the “Company,” stock code: 8158.HK, collectively the “Group”) is pleased to announce that the Group has obtained the registration certificate again for medical device (registration certificate number: National Armed Forces 20183461660) approved by China Food and Drug Administration (CFDA) for its product “ActivSkin”. This is the re-registration of the product’s medical device registration certificate. It does not only demonstrate the company’s confidence in the development of the products of tissue engineering, but also proves that the clinical efficacy and reliability of the product which has been launched for years, that is significant to the Group to continuously develop in the field of tissue engineering.

“ActivSkin” is the first and only tissue engineering product with active cells which is registered and approved by the China Food and Drug Administration (CFDA) and received the 1st class of 2011 National Science and Progress award as a subproject. It is an excellent product for repairing skin and have a very good therapeutic effect for burns and chronic ulcer wounds. A number of clinical cases related to “ActivSkin” have been accumulated since its launch years ago. It not only offers a stable curative effect, but also has a unique real epidermis double-layer active skin structure, which contains a lot of advantages such as good biocompatibility; low immunogenicity; cell induced healing, ensuring the advantages of graft skin survival. These advantages are highly appreciated by industry experts and a number of patients. At the same time, after continuous improvement, the performance and quality of the product have significantly improved through continuously review. The re-registered product passed the strict inspections of a number of national authorities such as the National Institutes for Food and Drug
Control (NIFDC), all technical indicators are in line with the requirements of specifications. The new registration certificate also abolished the restrictions on the use of the tertiary hospitals. The scale of clinical application will be greatly expanded as well as the market capacity.

In addition, the Company has inherited the business philosophy of “innovative technology, bring prosperity to public, support employees and contribute to society”. In the large-scale disaster incidents such as “7.5 Hangzhou bus arson”, “8.2 Suzhou plant explosion” in 2014, “6.27 Taiwan dust explosion” and “8.12 Tianjin Binhai New Area explosion” in 2015. The Company actively donated its products and took practical actions to support the victims. The successful approval of the re-registration also enables “ActiveSkin” to benefit more people and cure more patients continuously, constantly realize its social value with practical actions to achieve the Company’s core value for public health, contribute its own strengths for social stability. The successful of re-registration of “ActiveSkin” is significant for its three major business sectors and the layout of new domestic industries, it will benefit the company to maintain its technological advantages and leading position in the industry and ensure the sustained, healthy and stable development of various industries.

-End-

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited ("CRMI"), (Stock Code: 8158.HK), is a high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of CRMI ranges among five major sectors, namely tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and overseas business division. Headquartered in Hong Kong, CRMI has seven modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin, Changzhou and Hong Kong, and has evolved into a pioneering enterprise in tissue engineering and regenerative medicine in China. For more details, please visit www.crmi.hk